Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Scott H. Davis who wrote (2580)	1/16/2001 10:05:31 PM
From: Jibacoa	Read Replies (2) \| Respond to of 52153

VICL: Yes, I am quite familiar with VICL and have traded it several times over the years, the last time in August when I traded it from about 18 to 26. I remember an article in Barron's several years ago when J. Murphy (author ot the "technical letter")mentioned that his goal for VICL that year was 100. The stock was around 8 and I think it finished the year around 6. But I thought their "naked DNA" approach to gene transfer without a viral vector was interesting. They were also working (if I remember) on a vaccine for Malaria under a contract from the Navy. Their lead product candidate,as you mentioned,is Allovectin-7, which is in Phase III and Phase II trials for patients with advanced metastatic malignant melanoma,and also in a Phase II trial for patients with cancer of the head and neck. They also have another product, Leuvectin. which is in Phase II trials for patients with kidney and for patients with prostate cancer. Another product, VAXID, is a vaccine for non-Hodgkin's lymphoma and is in Phase I/II clinical trials. The stock appears to have made a bottom in the 14/12 area. The next resistance is now at the 19 1/2 to 19 7/8 level.(The Hs at year's end) and then the 21 1/2 to 22 (The double top of Dec.14 & 15). The money flow, which was positive in the last week in December, has been negative since the start of the new year. It closed today at 17 7/8 (up 4.38%) on volume of 106,800 with a B/A of 10/2 towards the close. I did not see any significant after hours trading. I would not trade VICL until I see the money flow turning positive and or having some good news. It still has also a lot of resistance in the 24 to 28 area from the trades that took place last September. Will see if the NASDAQ opens on the upside tomorrow with the good news on INTC after the close today. Bernard